Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$10.7 - $15.79 $207,580 - $306,326
-19,400 Reduced 64.65%
10,608 $114,000
Q3 2022

Nov 14, 2022

SELL
$9.76 - $13.41 $53,504 - $73,513
-5,482 Reduced 15.45%
30,008 $385,000
Q3 2021

Nov 15, 2021

BUY
$11.39 - $16.23 $404,231 - $576,002
35,490 New
35,490 $404,000

Others Institutions Holding KNSA

About Kiniksa Pharmaceuticals, Ltd.


  • Ticker KNSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,470,400
  • Market Cap $862M
  • Description
  • Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...
More about KNSA
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.